IMMXImmix Biopharma, Inc.
What is the market doing?
No clear lean: nothing decisive, though heavily shorted (+15% of shares).
Rangebound, no clear trend. Oversold (RSI 28). Price is −13% vs its 200-day average.
Heavily shorted, settled Sep 30, 2026, about a week of normal trading to cover.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How IMMX is trading
Immix Biopharma, Inc. is +163% over the past year while the S&P 500 is +16%: 147 points ahead of the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −13%
vs 200-day average · a clear downtrend
- RSI (14)
- 28
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 44%
Below its 52-week high
Details›
- Last close2026-10-23
- $8.14
- 1 monthS&P 500 −0.94%
- −30%
- 1 yearS&P 500 +16%
- +163%
- vs 50-day average$11.43
- −29%
- 52-week high
- $14.59
- 52-week low
- $3.03
- Annualised volatility
- 86%
| Year | Return |
|---|---|
| 2026 (year to date) | +56% |
| 2025 | +138% |
| 2024 | −68% |
| 2023 | +202% |
| 2022 | −36% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 5 | 3 of 5 | −3.5% |
| Feb | 5 | 1 of 5 | −5.7% |
| Mar | 5 | 1 of 5 | −6.5% |
| Apr | 5 | 2 of 5 | −2.5% |
| May | 5 | 3 of 5 | +9.2% |
| Jun | 5 | 3 of 5 | +10% |
| Jul | 5 | 2 of 5 | −2.6% |
| Aug | 5 | 2 of 5 | +5.4% |
| Sep | 5 | 1 of 5 | −3.8% |
| Oct | 5 | 3 of 5 | +9.4% |
| Nov | 4 | 4 of 4 | +26% |
| Dec | 4 | 4 of 4 | +38% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.